Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 5/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TSPO | P30536 | 2/20 | 0.36 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28069712 | 0.93 | FABP5 (0.45) | FABP5TSHRHTTMEN1KMT2A | |
| SCHEMBL4784032 | 0.92 | FABP5 (0.41) | FABP5TSHRHTTMEN1KMT2A | |
| SCHEMBL1526171 | 0.91 | FABP5 (0.40) | FABP5TSHRHTTMEN1KMT2A | |
| SCHEMBL6298094 | 0.91 | FABP5 (0.42) | FABP5TSHRHTTMEN1KMT2A | |
| SCHEMBL294203 | 0.91 | FABP5 (0.40) | FABP5TSHRHTTMEN1KMT2A | |
| SCHEMBL5372417 | 0.90 | FABP5 (0.39) | FABP5TSHRHTTMEN1KMT2A | |
| SCHEMBL5670740 | 0.89 | FABP5 (0.39) | FABP5TSHRHTTMEN1KMT2A | |
| SCHEMBL3433024 | 0.88 | HSD17B10 (0.39) | FABP5TSHRHTTMEN1KMT2A | |
| SCHEMBL2637405 | 0.87 | FABP5 (0.39) | FABP5MEN1KMT2ATSPO | |
| SCHEMBL3805522 | 0.87 | BMP1 (0.37) | FABP5TSHRHTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 597 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218042-A1 | MODIFIED LIPIDATED RELAXIN B CHAIN PEPTIDES AND THEIR THERAPEUTIC USE | SANOFI (FR) | 2024-07-04 | — | — | US | disclosed |
| EP-4392440-A2 | COMBINATION OF RELAXIN AND VASOPRESSIN ANALOGUES FOR TREATMENT OF RENAL DISORDERS OR CONDITIONS | River 2 Renal Corp. (US) | 2024-07-03 | — | — | EP | disclosed |
| US-11992537-B2 | Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2024-05-28 | — | — | US | disclosed |
| WO-2024071320-A1 | COMPOUND PRODUCTION METHOD | 国立大学法人東京大学 | 2024-04-04 | — | — | WO | disclosed |
| US-20240066132-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | NOVARTIS AG (CH) | 2024-02-29 | — | — | US | disclosed |
| WO-2023200897-A1 | USE OF VIRAL IL-6 IN CANCER THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-19 | — | — | WO | disclosed |
| US-11771657-B2 | Methods of delivering a neuroprotective polypeptide to the central nervous system | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-10-03 | — | — | US | disclosed |
| US-11752211-B2 | Fatty acids and their use in conjugation to biomolecules | NOVARTIS AG (CH) | 2023-09-12 | — | — | US | disclosed |
| US-11725036-B2 | Modified lipidated relaxin B chain peptides and their therapeutic use | SANOFI (FR) | 2023-08-15 | — | — | US | disclosed |
| WO-2023146807-A1 | VEGF MUTANTS AND MODULATION OF INTEGRIN-MEDIATED SIGNALING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-0672679-A1 | PHOSPHOLIPASE C INHIBITING PEPTIDE | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1995-09-20 | — | — | EP | disclosed |
| EP-0670729-A1 | TREATING RETINAL NEURONAL DISORDERS BY THE APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS | CEPHALON, INC. (US) | 1995-09-13 | — | — | EP | disclosed |
| WO-1995021194-A1 | SUPERACTIVE VIP ANTAGONISTS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-08-10 | — | — | WO | disclosed |
| EP-0670729-A4 | TREATING RETINAL NEURONAL DISORDERS BY THE APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS. | CEPHALON INC (US) | 1995-05-10 | — | — | EP | disclosed |
| WO-1994021684-A1 | BOTULINUM TOXIN POLYPEPTIDES AND THEIR USE AS VACCINE ENHANCING AGENTS | MICROBIOLOGICAL RESEARCH AUTHORITY (GB) | 1994-09-29 | — | — | WO | disclosed |
| EP-0604605-A1 | TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS | CEPHALON, INC. (US) | 1994-07-06 | — | — | EP | disclosed |
| WO-1994000486-A1 | NEUROPEPTIDE Y ANTAGONISTS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-01-06 | — | — | WO | disclosed |
| WO-1993020836-A1 | TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS | CEPHALON, INC. (US) | 1993-10-28 | — | — | WO | disclosed |
| WO-1993008826-A1 | TREATING RETINAL NEURONAL DISORDERS BY THE APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS | CEPHALON, INC. (US) | 1993-05-13 | — | — | WO | disclosed |
| WO-1993005011-A1 | NOVEL IMMUNOSUPPRESSANTS | SANDOZ LTD. (CH) | 1993-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11992537-B2 | Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy | MC1R, MC5R, MC3R | FABP5 3290/4885TSHR 65/4885HTT 1303/4885 |
| US-20240066132-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | FABP1, FABP2, FABP3 | FABP5 11/4885TSHR 828/4885HTT 2558/4885 |
| US-11752211-B2 | Fatty acids and their use in conjugation to biomolecules | FABP1, FABP2, FABP3 | FABP5 13/4885TSHR 620/4885HTT 2474/4885 |
| US-20240218042-A1 | MODIFIED LIPIDATED RELAXIN B CHAIN PEPTIDES AND THEIR THERAPEUTIC USE | RXFP1, RXFP2, RXFP4 | FABP5 141/4885TSHR 581/4885HTT 3577/4885 |
| US-11725036-B2 | Modified lipidated relaxin B chain peptides and their therapeutic use | SCTR, RXFP1, RXFP3 | FABP5 314/4885TSHR 40/4885HTT 3263/4885 |
| US-11771657-B2 | Methods of delivering a neuroprotective polypeptide to the central nervous system | GLP1R, IAPP, BDNF | FABP5 1487/4885TSHR 341/4885HTT 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.